Forty Seven Inc. to Report First Quarter 2019 Financial Results on Monday, May 13, 2019
May 06, 2019 16:05 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkin’s Lymphoma
April 26, 2019 08:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., April 26, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage company immuno-oncology company focused on developing therapies to activate macrophages in the...
Forty Seven Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
March 28, 2019 16:05 ET
|
Forty Seven, Inc.
-- Updated Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in Relapsed/Refractory Non-Hodgkin’s Lymphoma (r/r NHL) Expected in Second Quarter of 2019 –-- Updated Data from Phase 1b...
Forty Seven Inc. to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 28, 2019
March 21, 2019 16:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven Inc. to Present at Oppenheimer 29th Annual Healthcare Conference
March 12, 2019 08:00 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven Inc. to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day
February 07, 2019 08:00 ET
|
Forty Seven, Inc.
MENLO PARK, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven Inc. to Host Key Opinion Leader Breakfast Symposium on FSI-174, anti-cKIT Antibody, on January 22, 2019
January 15, 2019 08:00 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven Inc. Announces 2019 Strategic Priorities and Expected Milestones
January 07, 2019 08:00 ET
|
Forty Seven, Inc.
-- Updated Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab for r/r NHL Expected Mid-2019 -- -- Clinical Data from Two Additional Trials of 5F9 Expected in 2019 ---- Expanding Pipeline...
Forty Seven Inc. Reports Third Quarter 2018 Financial Results and Recent Business Highlights
November 13, 2018 08:00 ET
|
Forty Seven, Inc.
-- Advanced Oncology Pipeline with FSI-189, an Anti-SIRPα Antibody; Investigational New Drug (IND) Application-Enabling Studies Expected to Begin in 2019 –-- New England Journal of Medicine Published...
Forty Seven Inc. to Present at the Credit Suisse 27th Annual Healthcare Conference
November 07, 2018 08:00 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV) a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...